Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Shares Issued (2016 - 2025)

Ptc Therapeutics has reported Shares Issued over the past 13 years, most recently at $59.4 million for Q4 2025.

  • Quarterly results put Shares Issued at $59.4 million for Q4 2025, up 155.48% from a year ago — trailing twelve months through Dec 2025 was $93.1 million (up 225.93% YoY), and the annual figure for FY2025 was $93.1 million, up 225.93%.
  • Shares Issued for Q4 2025 was $59.4 million at Ptc Therapeutics, up from $16.8 million in the prior quarter.
  • Over the last five years, Shares Issued for PTCT hit a ceiling of $59.4 million in Q4 2025 and a floor of -$6.8 million in Q4 2022.
  • Median Shares Issued over the past 5 years was $3.0 million (2021), compared with a mean of $8.9 million.
  • Biggest five-year swings in Shares Issued: crashed 667.96% in 2022 and later surged 2089.47% in 2025.
  • Ptc Therapeutics' Shares Issued stood at $1.2 million in 2021, then crashed by 667.96% to -$6.8 million in 2022, then surged by 399.64% to $20.2 million in 2023, then rose by 14.88% to $23.2 million in 2024, then surged by 155.48% to $59.4 million in 2025.
  • The last three reported values for Shares Issued were $59.4 million (Q4 2025), $16.8 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.